Submission of bioequivalence test reports to be extended

The deadline for the bioequivalence test reports of about 250 drugs may be extended, as a number of pharmaceutical firms have failed to submit their test protocols because of a higher cost and tighter schedule, according to the Korea Food and Drug Administration.

The bio equivalency test reports of about 250 drugs should have been presented to the KFDA by the end of last month, but quite a n...